Emerging Markets, Biosimilars May Enhance Suitors' Interest In ratiopharm
Executive Summary
More than a year after being put up for sale, German generics firm ratiopharm is now said to have three serious suitors: generics giant Teva, Iceland's Actavis and Pfizer
You may also be interested in...
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe
The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.